Skip to main content
TipRanks
Go Ultimate75% OFF

Werewolf Therapeutics (HOWL) Stock Statistics & Valuation Metrics

806 Followers

Total Valuation

Werewolf Therapeutics has a market cap or net worth of $51.03M. The enterprise value is $2.95M.

Market Cap
$51.03M
Enterprise Value
$2.95M

Share Statistics

Werewolf Therapeutics has 48,599,068 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
48,599,068
Owned by Insiders
20.31%
Owned by Institutions
14.42%

Financial Efficiency

Werewolf Therapeutics’s return on equity (ROE) is -2.45 and return on invested capital (ROIC) is -173.37%.

Return on Equity (ROE)
-2.45
Return on Assets (ROA)
-0.88
Return on Invested Capital (ROIC)
-173.37%
Return on Capital Employed (ROCE)
-1.82
Revenue Per Employee
0
Profits Per Employee
-1.56M
Employee Count
39
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Werewolf Therapeutics is -1.79. Werewolf Therapeutics’s PEG ratio is -0.02.

PE Ratio
-1.79
PS Ratio
2.38
PB Ratio
7.41
Price to FCF
-2.09
Price to Operating Cash Flow
-2.09
PEG Ratio
-0.02

Income Statement

In the last 12 months, Werewolf Therapeutics had revenue of 0 and earned -60.82M in profits. Earnings per share was -1.32.

Revenue
0
Gross Profit
-1.63M
Operating Income
-60.68M
Pretax Income
-60.82M
Net Income
-60.82M
EBITDA
-53.91M
Earnings Per Share (EPS)
-1.32

Cash Flow

In the last 12 months, operating cash flow was -23.96M and capital expenditures 0, giving a free cash flow of -23.96M billion.

Operating Cash Flow
-23.96M
Free Cash Flow
-23.96M
Free Cash Flow per Share
-0.49

Dividends & Yields

Werewolf Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-48.33%
Earnings Yield
-56.73%

Stock Price Statistics

Beta
1.42
52-Week Price Change
12.57%
50-Day Moving Average
0.98
200-Day Moving Average
0.70
Relative Strength Index (RSI)
53.99
Average Volume (3m)
6.38M

Important Dates

Werewolf Therapeutics upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 25, 2027
Ex-Dividend Date
―

Financial Position

Werewolf Therapeutics as a current ratio of 1.62, with Debt / Equity ratio of 38.04%

Current Ratio
1.62
Quick Ratio
1.62
Debt to Market Cap
0.06
Net Debt to EBITDA
0.90
Interest Coverage Ratio
-11.50

Taxes

In the past 12 months, Werewolf Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Werewolf Therapeutics EV to EBITDA ratio is -0.50, with an EV/FCF ratio of -0.32.

EV to Sales
0.37
EV to EBITDA
-0.50
EV to Free Cash Flow
-0.32
EV to Operating Cash Flow
-0.32

Balance Sheet

Werewolf Therapeutics has $41.87M in cash and marketable securities with $0.00 in debt, giving a net cash position of $41.87M billion.

Cash & Marketable Securities
$41.87M
Total Debt
$0.00
Net Cash
$41.87M
Net Cash Per Share
$0.86
Tangible Book Value Per Share
$0.14

Margins

Gross margin is 80.41%, with operating margin of -90.91%, and net profit margin of -133.90%.

Gross Margin
80.41%
Operating Margin
-90.91%
Pretax Margin
-133.90%
Net Profit Margin
-133.90%
EBITDA Margin
-73.20%
EBIT Margin
-94.69%

Analyst Forecast

The average price target for Werewolf Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
―
EPS Growth Forecast
64.23%

Scores

Smart Score
4
AI Score
50